News Release 

Cellid, IVI exchange 'COVID-19 Vaccine Research Service Contract'

IVI to analyze samples from Phase 1/2a trials of Cellid's COVID-19 vaccine to evaluate immunogenicity

International Vaccine Institute

Science Business Announcement

January 5, 2021, SEOUL, Korea - Cellid and the International Vaccine Institute (IVI) have exchanged a collaborative research agreement to analyze the immunogenicity of the COVID-19 vaccine "AdCLD-CoV19".

Cellid and IVI announced on January 4 that they have signed a research service contract to cooperate in the clinical development of the "AdCLD-CoV19", a COVID-19 vaccine being developed by Cellid.

Under this contract, IVI will analyze samples from Phase 1/2a clinical trials of Cellid's COVID-19 vaccine "AdCLD-CoV19" to determine whether the AdCLD-CoV19 induced the right protective, or immune, responses.

As a bio-venture, Cellid is developing the COVID-19 vaccine "AdCLD-CoV19" based on an adenovirus vector. The company received an approval for a Phase 1/2a clinical trial plan (IND) from the Korean Ministry of Food and Drug Safety on December 4 last year. Following the approval, Cellid signed a contract with Korea University Guro Hospital, and is currently conducting clinical trials with the hospital.

In a challenge trial in a monkey infection model with Cellid's adenovirus vector-based COVID-19 vaccine, coronavirus was not detected at all in the upper respiratory and lung tissue two and three days after a single dose, which demonstrates the vaccine's excellent protective efficacy against the virus.

"Through cooperation in clinical development with IVI, which has extensive experience in collaboration with both domestic and international institutions in clinical trials and related activities, we redouble our efforts to confirm the safety and immunogenicity of AdCLD-CoV19 and to help ensure vaccine sovereignty based on reliable results," said Kang Chang-yul, CEO of Cellid. "In collaboration with IVI and other partners, we will expedite clinical trials with the aim of commercializing a COVID-19 vaccine as early as this summer."

IVI Director General Dr. Jerome Kim said, "IVI is pleased to partner with Cellid, a biotech specializing in development of cell-based immunotherapeutic vaccines. We will make the most of our experience and expertise in laboratory analysis and clinical evaluation of vaccines to support and accelerate the development of their COVID-19 vaccine."

###

About IVI's COVID-19 Program

IVI has partnered with vaccine developers around the world to accelerate multiple safe and effective vaccines as efficiently as possible. IVI is currently conducting early-stage clinical trials in South Korea with INOVIO's COVID-19 DNA vaccine candidate; establishing vaccine evaluation systems in partnership with Korean vaccine developers, the Korea Center for Disease Control and Prevention, and the UK's National Institute for Biological Standards and Control; developing COVID-19 vaccine adjuvants in the IVI lab; and conducting epidemiological studies in Burkina Faso and Madagascar to increase global understanding of the disease and promote equitable access to safe and effective COVID-19 vaccines. Learn more here.

About the International Vaccine Institute (IVI)

The International Vaccine Institute (IVI) is a nonprofit inter-governmental organization established in 1997 at the initiative of the United Nations Development Programme (UNDP). Headquartered in Seoul, South Korea, IVI was the first international organization hosted by Korea. IVI has 36 signatory countries and the World Health Organization (WHO) on its treaty, including Korea, Sweden, India, and Finland as state funders.

Our mandate is to make vaccines available and accessible for the world's most vulnerable people. We focus on infectious diseases of global health importance such as cholera, typhoid, shigella, salmonella, schistosomiasis, chikungunya, group A strep, Hepatitis A, HPV, TB, HIV, MERS, COVID-19, as well as antimicrobial resistance. For more information, please visit https://www.ivi.int

CONTACT

Aerie Em, Global Media & Communications Specialist
+82 2 881 1386 | aerie.em@ivi.int

Disclaimer: AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert system.